iBio Q1 FY2026 revenue $0.1M; cash $49.6M; IBIO-610 half-life up to 100 days

iBio, Inc.

2026-Q1 EPS reported -$0.11 vs consensus -$0.06 ▼ miss (-72.1%)

Revenue $0.1M vs $0 prior year; R&D expenses $3.6M (up $2.3M YoY); G&A $2.5M (down $0.3M).
Cash $49.6M as of Sept 30, 2025, expected to fund operations into Q4 FY2027.
Closed $50M public offering; potential additional $50M from common warrant exercise for total up to $100M.
IBIO-610 NHP data shows predicted human half-life up to 100 days, enabling potential twice-yearly dosing.
Regained Nasdaq compliance on Nov 4, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.